Longevity science is starting to ask a deeper question: What if aging well is about more than keeping the body alive longer? UC Berkeley’s new study is looking at the aging brain through the lens of plasticity, memory, emotion, perception, and overall well-being. The focus is healthy older adults. So much of aging research begins after something has already gone wrong: memory loss, cognitive decline, disease, or diagnosis. This study is more proactive. It looks at whether the brain later in life may still have more room to adapt, reorganize, and stay flexible than we usually assume. Researchers will use MRI scans and follow-up assessments to look for measurable changes in brain structure, brain activity, emotional regulation, social connection, awe, and stress recovery. That makes this less about “anti-aging” in the shallow sense and more about successful aging. Can the brain remain open to change? Can older adults maintain deeper emotional resilience? Can science better understand the biology of aging well before decline begins? That may be one of the most important questions in longevity. Because living longer only matters if the mind, memory, and sense of connection can come with us.

Robert Edward Grant says humanity may be entering a stage where we have to unlearn what we thought we knew. But this is not just about changing ideas. It is about noticing the beliefs, fears, and inner resistance that quietly shape the way we move through life. In the full conversation, Grant connects this to mentalism, the idea that consciousness and perception are deeply woven into reality itself. His point is not simply “think positive,” but to stop feeding the self-limiting stories that keep us stuck. The more we replace judgment with awareness, gratitude, and love, the more life starts to look less like something happening to us… and more like something revealing itself through us. Robert has built companies, developed medical innovations, and explored the intersections of mathematics, health, consciousness, and human potential. His work sits at the frontier of fields rarely studied together, investigating patterns that suggest there may be more to human health and human potential than we currently understand. We’re excited to welcome @Robert_E_Grant_ as a speaker at Super Human Network 2026. June 13 | Super Human — The Global Human Improvement Summit 2026 | Invite-only

David Sinclair’s Information Theory of Aging starts with a fascinating idea: Aging may not just be the body wearing down. It may be the body slowly losing access to the information that helps cells function young.

Now this theory is moving closer to human testing. Life Biosciences, a company co-founded by Sinclair, received FDA clearance for a Phase 1 trial testing partial epigenetic reprogramming in age-related eye disease. It is an early safety trial, but it marks a major step for one of longevity science’s biggest ideas.

A weight loss drug may have just opened a new conversation around alcohol use disorder. In a new Lancet study, researchers tested once-weekly semaglutide, the drug sold as Wegovy, in people with both obesity and alcohol use disorder. The results were hard to ignore. Patients receiving semaglutide went from an average of about 17 heavy drinking days per month to roughly 5 after 26 weeks. The placebo group improved too, dropping from about 17 to roughly 9 heavy drinking days per month. That matters because both groups also received cognitive behavioral therapy focused on motivation, cravings, and relapse prevention. So this wasn’t “drug versus nothing.” It was semaglutide plus therapy compared against placebo plus therapy. And the semaglutide group still saw a larger reduction. They also reduced total alcohol intake by an extra 467 grams per month compared to placebo, had fewer drinks per drinking day, and reported lower craving scores. Researchers believe this may have something to do with GLP-1 receptors in the brain’s reward pathways. In plain English: The same system involved in appetite, cravings, and reward may also influence the drive to keep drinking. That could help explain why some people taking these medications report losing interest in alcohol, even when that wasn’t the original goal. Still, this is early. The trial focused on people with obesity and alcohol use disorder, so we need larger studies, longer follow-up, head-to-head comparisons, and research in people without obesity before this becomes a standard addiction treatment. But as an early signal, it’s a big one. This post is for educational purposes only and should not be taken as medical advice. Always speak with a qualified medical professional before starting, stopping, or changing any medication or treatment plan.